welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
study id #: NCT02592941
condition: Duchenne Muscular Dystrophy
status: approved for marketingpurpose:
The expanded access program will provide access to treatment with deflazacort in children, adolescent, and adult patients with DMD in the U.S. who are ineligible, unable, or otherwise unwilling to enroll in a clinical study examining the efficacy of deflazacort while a new drug application is under preparation and review. Enrollment is open to all eligible patients.
mechanism of action: Glucocorticoid to delay decline in muscle strength
last updated: November 22, 2018
Deflazacort will be supplied free of charge and shipped directly to patients or caregivers, as appropriate. Treating physicians will continue to follow their standard of care activities and procedures for management of DMD. Treating physicians participating in the expanded access program are required to collect/document any patient or caregiver reported safety events and report to the sponsor.
• Confirmed diagnosis of Duchenne muscular dystrophy
• The patient is >=5 years old
• Current on all childhood vaccinations including the chicken pox vaccine
• History or current medication condition that could affect safety or poses an additional risk
• Hypersensitivity or allergic reaction to steroids or their formulations
A Comparison of the Effects of Deflazacort and Prednisone Versus Placebo on Timed Functional Tests in Boys with Duch...Objective: To describe the timed motor ...
The impact of deflazacort on puberty in Duchenne muscular dystrophyBackground: The routine use of glucocor...
An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability DeflazacortThis is an open label, long-term extensi...
Effect of Deflazacort and Prednisone on Muscle Enzymes in the Treatment of Duchenne Muscular DystrophyObjective: To describe the effects of d...
ICER Releases Draft Evidence Report on Treatments for Duchenne Muscular DystrophyThe Institute for Clinical and Economic ...
PTC Therapeutics Announces Publication of Data Demonstrating the Clinical Differentiated Benefit of DeflazacortPTC Therapeutics, Inc. today announced t...
Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapyQuality of life in Duchenne Muscular Dys...